CD8A and neoplasm: diABZI combined with 1-MT could be a promising option for CRC.diABZI combined with indoleamine 2,3 dioxygenase inhibitor 1-MT induced tumor regression, promoted the recruitment of CD8+ T cells and DCs, limited the infiltration of myeloid-derived suppressor cells, prolonged the survival time of CRC mice in a STING-dependent manner.